Duke University discovers the latest cancer cell therapy: kills refractory breast cancer
Recently, a new study published by Duke University scientists at Oncogene reported that a cell of a malignant and drug-resistant breast cancer (called triple-negative breast cancer, TNBC) is deprived of the key to cystine. When you have nutrients, you will die quickly. By studying the causes of cell death, they found that this "cystine addiction" is triggered by a mechanism by which multiple tumor cells detach and migrate to new body parts. Cancer can reactivate the metabolism of tumor cells and turn them into "thin and sputum" replication machines. However, just as Olympic athletes rely on special diets to complete the game, the extremely exciting metabolism of tumor cells allows them to rely on specific nutrients to survive. For years, scientists have been trying to identify and understand the "desires" of these cells in order to develop new cancer therapies that prevent tumors from acquiring the necessary nutrients to starve the tumor. On November 21, a new study published by Duke University scientists at Oncogene reported that a malignant and drug-resistant breast cancer (called triple-negative breast cancer, TNBC) cells, when deprived of cystatin When the key nutrients of acid are used, they will die quickly. By studying the causes of cell death, they found that this "cystine addiction" is triggered by a mechanism by which multiple tumor cells detach and migrate to new body parts. Jen-Tsan Ashley Chi, a senior author of the study and associate professor of molecular genetics and microbiology at Duke University, said: "This process is well known and appears in metastatic cancer cells. We have found that this also makes cells cytosine Acid addiction. This is good news, because these are the cells we really want to get rid of." These results suggest that blocking cystine uptake is not only an effective treatment for triple-negative breast cancer, but it can also treat other malignancies that use this pathway during metastasis. Patients diagnosed with triple-negative breast cancer account for 10 to 20 percent of all breast cancer patients, with few treatment options other than surgery and chemotherapy. This is because most successful breast cancer therapies target two of the three receptors (estrogen receptor, progesterone receptor or Her2/neu receptor) that are ubiquitous in tumor cells, but three Negative breast cancer cells lack these three receptors. Some studies suggest that cells without cystine cannot survive, and this molecule is formed by the joining of two portions of cysteine. Earlier this year, a study published by Chi's research team showed cysteines from cells of a malignant kidney tumor. (Another study of "starved" cancer cells) To understand whether triple-negative breast cancer is also the case, Xiaohou Tang, a former postdoctoral researcher at Chi Laboratories, has nourished triple-negative breast cancer and estrogen receptor-positive breast cancer cells. Deprivation test: Each cell was grown in batches in a series of different growth media, with only one of 15 key amino acids missing in each batch. Chi said that most cells do not respond to these small changes in the diet. But there is a notable exception. "Three-negative breast cancer cells are very sensitive to cystine, so if you remove cystine, they die quickly, while other breast cancer cells don't care," he said. Urostomy Bag,Ileal Conduit Bag,Urostomy Bag Covers,Urine Ostomy Bag Wenzhou Celecare Medical Instruments Co.,Ltd , https://www.wzcelecare.com